NEW YORK ( TheStreet) -- CHANGE IN RATINGSAbbvie ( ABBV) was downgraded at BMO Capital to market perform from outperform. Valuation call, based on a $42 price target, BMO Capital said. BBX ( BBX) was upgraded to hold at TheStreet Ratings. Coca-Cola Enterprises ( CCE) was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $40 price target, Goldman said. CEC Entertainment ( CEC) was downgraded to hold at TheStreet Ratings. Clean Harbors ( CLH) was upgraded at Oppenheimer to outperform from perform. $72 price target. Company is seeing higher end-market demand and has better potential for revenue synergy, Oppenheimer said. eBay ( EBAY) was upgraded at Canaccord Genuity to buy from hold. $67 price target. Marketplaces and PayPal can continue to drive growth, Canaccord said. $67 price target. General Mills ( GIS) was downgraded at Morgan Stanley to equal-weight from overweight. $49 price target. Company lacks near-term catalysts, Morgan Stanley said. Intel ( INTC) was downgraded at JMP Securities to market perform from outperform. Company will no longer pursue the Haswell architecture, JMP Securities said. News Corp. ( NWSA) was upgraded at Credit Suisse to outperform from neutral. $36 price target. Company should see higher cable growth and margin expansion, Credit Suisse said. RF Micro ( RFMD) was upgraded at Canaccord Genuity to buy from hold. $7 price target. Company can gain share in the LTE smartphone market, Canaccord Genuity said. Regal Entertainment ( RGC) was downgraded at MKM Partners to neutral from buy. Company lacks near-term catalysts, MKM said. Valassis ( VCI) was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, based on a $36 price target, Lazard Capital Markets said. Yahoo! ( YHOO) was downgraded at Pivotal Research Group to hold from buy. Valuation call, based on a $26 price target, Pivotal Research said. STOCK COMMENTS/EPS CHANGES Alexion Pharmaceuticals ( ALXN) numbers were cut at UBS. Shares are now seen reaching $120. Estimates were also lowerd on FDA warning letter and EU updates, UBS said. Buy rating. BlackBerry ( BBRY) estimates were raised at UBS through 2015. Quarter comforted by margin, lean channel, enterprise prospects, and guidance, UBS said. Neutral rating and $13 price target. Biogen Idec ( BIIB) numbers were raised at UBS. Shares are now seen reaching $200. Estimates were also raised on lower risk, BG-12 pricing, UBS said. Neutral rating.